Explore

Trendline Trendline
GE HealthCare Expands AI Mammography Collaboration with RadNet's DeepHealth to Enhance Breast Cancer Screening

GE HealthCare Expands AI Mammography Collaboration with RadNet's DeepHealth to Enhance Breast Cancer Screening

GE HealthCare Expands AI Mammography Collaboration with RadNet's DeepHealth to Enhance Breast Cancer Screening
Trendline Trendline
GE HealthCare Expands AI Mammography Collaboration with DeepHealth to Enhance Breast Cancer Screening

GE HealthCare Expands AI Mammography Collaboration with DeepHealth to Enhance Breast Cancer Screening

GE HealthCare Expands AI Mammography Collaboration with DeepHealth to Enhance Breast Cancer Screening
Trendline Trendline
GE HealthCare and DeepHealth Enhance AI Mammography Tools for Improved Cancer Detection

GE HealthCare and DeepHealth Enhance AI Mammography Tools for Improved Cancer Detection

GE HealthCare and DeepHealth Enhance AI Mammography Tools for Improved Cancer Detection
Rapid Read Rapid Read
GE HealthCare Expands AI Mammography Collaboration to Enhance Breast Cancer Screening

GE HealthCare Expands AI Mammography Collaboration to Enhance Breast Cancer Screening

GE HealthCare has announced an expanded collaboration with DeepHealth, Inc., a subsidiary of RadNet, Inc., to advance AI-powered mammography tools. This collaboration aims to enhance breast cancer screening capabilities by integrating DeepHealth's Breast Suite AI with GE HealthCare's Pristina Via mammography system. The initiative, first launched in 2024, seeks to improve image interpretation and operational efficiency in breast cancer detection. The expanded collaboration will introduce new applications designed for compatibility with GE HealthCare's mammography systems, including ProFound Pro and Safeguard Review, which offer automatic lesion localization and density assessment. These advancements are showcased at the Society of Breast Imaging's Annual Symposium, highlighting GE HealthCare's commitment to precision care in women's health.
Trendline Trendline
GE HealthCare Expands AI Mammography Collaboration with DeepHealth for Enhanced Breast Cancer Screening

GE HealthCare Expands AI Mammography Collaboration with DeepHealth for Enhanced Breast Cancer Screening

GE HealthCare Expands AI Mammography Collaboration with DeepHealth for Enhanced Breast Cancer Screening
Rapid Read Rapid Read
AI Revolutionizes Cancer Drug Discovery with Faster, Personalized Therapies

AI Revolutionizes Cancer Drug Discovery with Faster, Personalized Therapies

AI is transforming the landscape of cancer drug discovery by enabling faster and more personalized treatment development. Recent advancements have allowed AI to accelerate the identification of promising drug candidates and improve patient stratification. However, challenges such as data bias, regulatory uncertainty, and insufficient clinical validation remain. AI-driven drug discovery has led to the development of AI-generated small molecules that have entered clinical trials, showcasing the potential for AI to revolutionize precision oncology. Despite these advancements, the integration of AI in drug development faces hurdles that need to be addressed to maximize its potential.
Trendline Trendline
AI's Role in Cancer Drug Discovery: Accelerating Precision Oncology

AI's Role in Cancer Drug Discovery: Accelerating Precision Oncology

AI's Role in Cancer Drug Discovery: Accelerating Precision Oncology
Rapid Read Rapid Read
AI Tool SIDISH Identifies High-Risk Cells in Aggressive Cancers, Aiding Targeted Therapy Development

AI Tool SIDISH Identifies High-Risk Cells in Aggressive Cancers, Aiding Targeted Therapy Development

Researchers have developed an artificial intelligence tool named SIDISH, which stands for semi-supervised iterative deep learning for identifying single-cell high-risk populations. This tool is designed to identify small groups of cells that are most responsible for driving aggressive cancers. By focusing on these high-risk cells, SIDISH offers a more precise approach to designing targeted therapies, as it highlights which cells within a tumor are most strongly linked to poor patient outcomes. The tool was tested on pancreatic, breast, and lung cancers, successfully identifying high-risk cells using tumor samples from patients. SIDISH connects detailed single-cell data with patient outcomes, a challenge that has long existed in cancer research. The tool can also simulate how these high-risk cells respond to specific genetic changes, potentially identifying promising drug targets.
Trendline Trendline
Perceptive Discovery Partners with MH3D to Launch α-Sight for Enhanced Radiopharmaceutical Imaging

Perceptive Discovery Partners with MH3D to Launch α-Sight for Enhanced Radiopharmaceutical Imaging

Perceptive Discovery Partners with MH3D to Launch α-Sight for Enhanced Radiopharmaceutical Imaging
Trendline Trendline
Philips Receives FDA Clearance for AI-Powered Spectral CT System Verida

Philips Receives FDA Clearance for AI-Powered Spectral CT System Verida

Philips Receives FDA Clearance for AI-Powered Spectral CT System Verida
Rapid Read Rapid Read
ClearNote Health to Present Advanced Pancreatic Cancer Detection Test at AACR 2026

ClearNote Health to Present Advanced Pancreatic Cancer Detection Test at AACR 2026

ClearNote Health, a company focused on early cancer detection, is set to present its Avantect® Pancreatic Cancer Test at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The test, which utilizes the company's Virtuoso™ epigenomics platform, offers a noninvasive method to detect pancreatic cancer with a sensitivity of 82.6% and specificity of 97.5%. This technology measures active biological differences between cancerous and healthy cells using a blood sample. The test is particularly aimed at high-risk groups, such as those with genetic predispositions or a family history of pancreatic cancer. ClearNote Health will also present data on the use of cell-free DNA-based epigenomic profiling to predict treatment responses, which could lead to the development of new blood-based biomarkers.
Trendline Trendline
Mount Sinai and SOPHiA GENETICS Collaborate to Enhance Precision Cancer Care

Mount Sinai and SOPHiA GENETICS Collaborate to Enhance Precision Cancer Care

Mount Sinai and SOPHiA GENETICS Collaborate to Enhance Precision Cancer Care